Dose of cosentyx?

What is the typical dose of Cimzia, not Cosentyx?

However, given that Cosentyx and Cimzia are both biologics used to treat various inflammatory diseases, we will still explore the doses of Cosentyx.

Cosentyx (secukinumab) is an interleukin-17A inhibitor used to treat psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and Crohn's disease [1]. According to the prescribing information, the typical dose of Cosentyx is 300 mg administered via subcutaneous injection every week, which may be continued for as long as needed [2].

However, some patients may require a higher dose of 150 mg administered via subcutaneous injection twice a week [2].

Please note that these dosing regimens may not be suitable for everyone, and a healthcare professional should be consulted to determine the best dosing schedule.

Can biosimilars enter the market before patent expiry?

Under the Biologics Price Competition and Innovation Act (BPCIA), the pathway for biosimilar approval involves an Abbreviated Biologics License Application (aBLA) to establish biosimilarity to the reference product. Once approved by the FDA, biosimilars can enter the market before the patent expires [3].

However, please note that this does not impact the existing patent protection granted to the reference product.

Are there any side effects associated with Cosentyx?

Yes, Cosentyx has been associated with several side effects, including injection site reactions, such as redness, swelling, and itching, which are usually mild and temporary [1]. Other notable side effects may include gastrointestinal issues, skin reactions, and allergic reactions [1].

If you have any concerns about Cosentyx or its dosing schedule, consult your healthcare professional.

Sources:

[1] Novartis Pharmaceuticals Corporation. (2022). Cosentyx (secukinumab) injection, for subcutaneous use [Package insert]. Retrieved from www.cosentyx-hcp.com.

[2] Cosentyx. (n.d.). About Cimzia. Retrieved from https://www.cosentyx-hcp.com/about-cosentyx

[3] U.S. Food and Drug Administration. (2022). Biosimilars: Frequently Asked Questions. Retrieved from https://www.fda.gov/drugs/biosimilars-frequently-asked-questions